Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria

Phase 2

Recruiting

• Conditions: Hypercalcemia, Idiopathic, of Infancy; Hypercalciuric Hypercalcemia; Hypercalciuria; Idiopathic Infantile Hypercalcaemia - Severe Form; Genetic Disease; Idiopathic Infantile Hypercalcemia - Mild Form
• Interventions: Drug: Rifampin

• Registration Number: NCT03301038
• Lead Sponsor: Children's Hospital of Philadelphia

Brief Summary

This study evaluates the efficacy of rifampin in the treatment of hypercalcemia and/or hypercalciuria in participants with at least one inactivating mutation of the CYP24A1 gene. Eligible subjects will receive rifampin for a total of 16 weeks during this study.

Detailed Description

Idiopathic infantile hypercalcemia (IIH; omim 143880) is a genetic disorder of mineral metabolism characterized by severe hypercalcemia and/or hypercalciuria, suppressed serum levels of parathyroid hormone (PTH) and elevated levels of the active vitamin D metabolite, 1,25(OH)2D. Biallelic inactivating mutations of CYP24A1, the gene encoding the 24-hydroxylase enzyme that represents the principal pathway for inactivation of vitamin D metabolites, cause the most common and severe form of IIH.

Investigators have preliminary data supporting a novel therapeutic approach to repurpose rifampin as an agent to induce over-expression of CYP3A4 and CYP3A5, enzymes that are expressed in the liver and intestine. When these enzymes are induced, the increased enzyme activity provides an alternative catabolic pathway for inactivation of vitamin D metabolites. The purpose of this study is to obtain support for an open label, escalating dose study to assess the effect, safety, and tolerability of once daily oral rifampin in participants with IIH due to inactivating mutations in CYP24A1.

In this study, Investigators will recruit 60 patients with at least one inactivating mutation of CYP24A1. Participants will be observed for 8-weeks before a 16-week treatment phase of rifampin and 8 further weeks of observation. In addition to following the effect of treatment on calcium homeostasis, Investigators will also study the pharmacokinetics of rifampin in this condition and the effect on intestinal calcium absorption.

Study Timeline

• Study First Submitted: 2017-09-01
• Study First Submitted QC: 2017-09-29
• Study First Posted: 2017-10-04
• Study Start: 2018-07-25
• Status Verified: 2024-08
• Last Update Submitted: 2024-08-05
• Last Update Posted: 2024-08-07
• Primary Completion: 2026-12
• Study Completion: 2030-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Males or females age 6 months to 65 years.
• at least one mutations of CYP24A1
• Serum and/or urinary calcium above the normal reference range for age
• Serum PTH concentration <20 pg/ml
• Elevated or normal serum concentration of 1,25-dihydroxyvitamin D3.

Exclusion Criteria

• Parents/guardians or subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.
• Allergy to rifampin or related medications
• Current therapies with medications that have significant drug-drug interactions with rifampin, defined as a medication considered to interact with CYP3A4 or CYP3A5 and either induce or inhibit expression or function of these P450 enzymes. By "drug-drug" interactions we are looking for medications that will affect metabolism or action of rifampin as exclusionary, not medications that will be affected by rifampin.
• Pregnancy or breastfeeding
• Laboratory abnormalities that indicate clinically significant hepatic, or renal disease:

Aspartate Aminotransferase (AST/SGOT) > 2.0 times the upper limit of normal Alanine aminotransferase (ALT/SGPT) > 2.0 times the upper limit of normal Total bilirubin > 2.0 times the upper limit of normal Creatinine > 2.0 times the upper limit of normal

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
All Subjects	Rifampin	SingleArm: Escalating doses of rifampin (5 and 10 mg/kg/day) (SingleArm)

Primary Outcome Measures

Name	Time	Method
Serum parathyroid hormone	up to 32 weeks	Measured at baseline and every 4 weeks
Urinary calcium excretion	up to 32 weeks	Measured at baseline and every 4 weeks
Serum albumin-adjusted calcium	up to 32 weeks	Measured at baseline and every 4 weeks

Secondary Outcome Measures

Name	Time	Method
Rifampin pharmacokinetics	8, 16 and 24 weeks post-dose	Measured three times during the study
Nephrocalcinosis	Baseline and week 32	Renal ultrasound performed before and after treatment
Intestinal calcium absorption	baseline, 8, 16, 24 and 32 weeks post-dose	Measured using stable calcium isotopes five times during the study

Trial Locations

Locations (1)

Children's Hospital of Philadelphia; 🇺🇸 Philadelphia, Pennsylvania, United States